FDA declines to approve Motif Bio’s iclaprim for ABSSSI treatment

This article was originally published here

In the complete response letter (CRL) it issued to the company, the FDA said that it cannot approve the New Drug Application (NDA) of iclaprim in its present

The post FDA declines to approve Motif Bio’s iclaprim for ABSSSI treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply